BIODANE PHARMA A/S: Financial statements 2023
CVR: 28310102
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
BIODANE PHARMA A/S (CVR 28310102) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 3,070,739 and a net result of DKK 900,246 compared with DKK 586,354 the year before. That is an increase of 29.5% compared with the year before. Equity in the 2023 report amounted to DKK 3,542,764. The solvency ratio was 82.7%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 3,070,739
- Profit/Loss
- DKK 900,246
- Equity
- DKK 3,542,764
- Total Assets
- DKK 4,282,675
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 3.1 mio. | 900 t. | 3.5 mio. | 1 |
| 2022 | - | 2.4 mio. | 586 t. | 4.6 mio. | 1 |
| 2021 | - | 3.7 mio. | 1.9 mio. | 4.1 mio. | 1 |
| 2020 | - | 1.6 mio. | 500 t. | 2.2 mio. | 1 |
| 2019 | - | 1.5 mio. | 257 t. | 1.7 mio. | 1 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
BIODANE PHARMA A/S has published its annual report for 2022. Gross profit came to DKK 2,371,672, and the net result was DKK 586,354.
About BIODANE PHARMA A/S
BIODANE PHARMA A/S is a Danish company of the type Aktieselskab based in Gesten, founded in 2004. The company is registered under the industry Fremstilling af andre fødevarer i.a.n.. The company was previously named BIODANE PHARMA ApS and BIOFIBER TØRRING ApS. The management consists of Gunner Kreutzer Jakobsen. The board consists of Peter Gæmelke (chair), Flemming Torben Heden Knudsen, Gunner Kreutzer Jakobsen and Rasmus Juhl Rasmussen. The company is owned by BIODAN A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 2,534,166 and a net result of DKK 182,862 compared with DKK 1,651,356 the year before. Equity in the 2025 report amounted to DKK 2,505,002.